Glucosamine Chondroitin Msm

Verify with FDA CVM →

12 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Glucosamine Chondroitin Msm

Administration Routes

Oral

Species Affected

Dog 12

Most Affected Breeds

Spaniel - King Charles Cavalier 12

Most Reported Reactions

Cough 3
Congestive heart failure 3
Skin lump 2
Other abnormal test result NOS 2
Scratching 1
Ear infection NOS 1
Anxiety 1
Arrhythmia 1
Panting 1
Oral mass 1
Dermal mass 1
Difficulty going up/down stairs 1

Outcome Breakdown

Recovered/Normal
6 (50.0%)
Outcome Unknown
6 (50.0%)

Data Summary

Metric Value
Total adverse event reports 12
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 1
Distinct reactions reported 12
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine Chondroitin Msm Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 12 adverse event reports referencing Glucosamine Chondroitin Msm, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine Chondroitin Msm. Reported administration route is Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine Chondroitin Msm reports are Dog (12 reports), with Dog accounting for the largest share. Within those species, Spaniel - King Charles Cavalier (12) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine Chondroitin Msm are Cough (3), Congestive heart failure (3), Skin lump (2), Other abnormal test result NOS (2). Of the 12 reports with a coded outcome, Recovered/Normal is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine Chondroitin Msm.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial